Incyte says Phase 1/2 data show 81% median bleed-rate cut with VWD drug latarcibart
INCY•Safety findings
The safety profile appeared favorable; three treatment-related adverse events were reported, including Grade 2 headaches and a Grade 1 injection-site reaction.
Phase 1/2 data support pivotal development
Incyte says it disclosed Phase 1/2 multidose data for VGA039 (latarcibart) in von Willebrand disease, supporting ongoing pivotal Phase 3 development.
Across 16 patients, median annualized bleeding rate fell 81% with once-monthly subcutaneous dosing; reductions were reported across all VWD types.
Results in patients switching from IV prophylaxis
Patients switching from VWF-containing IV prophylaxis saw 75%-100% bleed reductions, suggesting potential improvement versus current prophylactic practice.
